AI Assistant
Blog
Pricing
Log In
Sign Up
Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
